



HOPA

Hematology/Oncology Pharmacy Association

FOR IMMEDIATE RELEASE

Contact: Suzanne Simons
Executive Director
847.375.4896
ssimons@hoparx.org

HOPA Announces the 2017 Class of Fellow of the Hematology/Oncology Pharmacy Association

Chicago, IL (May 23, 2017): The Hematology/Oncology Pharmacy Association (HOPA) is pleased to announce the 2017 class of Fellow of the Hematology/Oncology Pharmacy Association (FHOPA). This designation recognizes individuals who have made sustained contributions to HOPA and who also have demonstrated exceptional performance in oncology pharmacy. The 2017 class of HOPA Fellows are:

Sally Yowell Barbour, PharmD BCOP CPP FHOPA, is the Director of Oncology Pharmacy Programs, PGY2 Oncology Pharmacy Residency Program Director and a Clinical Pharmacist Practitioner at Duke University Medical Center. She maintains a clinical practice in the adult outpatient oncology clinics. She earned her BA from Duke University and her PharmD degree from the University of Texas at Austin. She completed a residency in Pharmacy Practice at the University of Illinois at Chicago and in Oncology Pharmacy Practice at the Audie L. Murphy VA and University of Texas Health Science Center in San Antonio. She has been a board certified oncology pharmacist since 2001 and obtained her Clinical Pharmacist Practitioner certification in 2005. Dr. Barbour serves as a member of the NCCN Antiemesis Panel, NCCN Educational Programs Advisory Committee, ASCO Antiemetic Guideline Panel, and the Pharmacy Committee for the Alliance for Clinical Trials in Oncology. She has served on various HOPA committees as both a member and committee leader and has given numerous international, national, and local professional presentations. In 2001, she co-founded the North Carolina Oncology Pharmacists Association.

John Kuhn, PharmD BS FHOPA, received his BS degree in Pharmacy (1972) and PharmD (1977) from the UT, College of Pharmacy. He completed a residency in Pediatric/Adult

Oncology. Dr. Kuhn, Professor of Translational Oncology, is a member of the IVY Foundation Early Phase Clinical Trials Consortium using molecular profiling to guide individualized treatment of adults with glioblastoma. Dr. Kuhn co-developed the Osteoport. This device spurred the development of EZ-IO, which changed emergency medicine practices for both adults and children. He has authored over 400 publications, abstracts and book chapters. He has been acting editor for the journal of *Investigational New Drugs (IND)*. Dr. Kuhn is the recipient of a wide-ranging array of awards and honors, most notable, HOPA (2006) named their annual Keynote Lecture in his name. He is an ACCP fellow. He was Board Certified in Oncology Pharmacy from 2000-2013. Dr. Kuhn served as Acting President/Past President of HOPA from 2004-2006. The most significant part of his career is having a part in the education and training of outstanding Oncology/Hematology Pharmacy residents and fellows.

Susanne Liewer, PharmD BCOP FHOPA, completed her B.S. (Biology) and PharmD from the University of Nebraska. She also completed Pharmacy Practice and Oncology Specialty residencies at the University of Kentucky and became a board certified oncology pharmacist in 2003. Dr Liewer has worked as a clinical oncology pharmacist in a variety of settings including academic medical centers and pediatric stem cell transplant. Currently, Dr Liewer is the clinical pharmacy coordinator for stem cell transplant and hematologic malignancies at Nebraska Medicine and the PGY2 Oncology Pharmacy Residency Director. In addition, Dr. Liewer is a Clinical Associate Professor at the University Of Nebraska Medical Center College Of Pharmacy.

Dr Liewer is a past HOPA Board Member and has been active in HOPA for more than ten years serving on several committees and task forces. She is also an active member in other professional pharmacy organizations. Dr Liewer's clinical research interests focus on hematologic malignancies, immunosuppression, and immunocompromised-related infections. She has authored numerous articles and book chapters on hematologic malignancies and stem cell transplant.

Kerry Parsons, PharmD BCOP FHOPA, currently is a Medical Science Liaison specializing in research to address unmet needs for patients diagnosed with cancers and other diseases. She obtained her BS and PharmD degrees at Auburn University and Creighton University, respectively. As a former clinician at Children's of Alabama, Dr. Parsons focused her practice, academic and research activities on cancers that namely affect children, adolescents and young adults. Her enthusiasm for this work is reflected in numerous activities including research

abstracts, presentations, and invited and peer-reviewed publications. She maintains an active role in many organizations including HOPA, PPAG, and the Children's Oncology Group and exhibits significant devotion to patient advocacy and mentorship. Past recognition of her endeavors includes a Research Grant from HOPA and the Young Alumni Appreciation Award from Creighton University. Dr. Parsons holds great enthusiasm about HOPA and the expanding future of oncology pharmacy practice throughout the cancer community.

Timothy Tyler, PharmD FCSHP FHOPA, is the Director of Pharmacy, Lab and Oncology Supportive Care Services at the Comprehensive Cancer Center on the campus of Desert Regional Medical Center in Palm Springs, California. His additional responsibilities include pain management and co-chairing the complementary medicine committee. He has served as adjunct clinical faculty at the University of Southern California School of Pharmacy for the past 20 years.

Dr. Tyler received his undergraduate degree in Business Administration from the California State University, San Bernardino and he received his Doctor of Pharmacy degree from the University of Southern California in Los Angeles. He was instrumental in the creation of the pharmacy residency program at Desert Hospital in Palm Springs as its first resident in 1993. In 2006, Dr. Tyler completed a 4.5 year appointment to the Medicare Federal Advisory Panel for Ambulatory Payment Classification for which he chaired the Data Subcommittee for his last 2 years. He has keynoted several national and international meetings and is a much sought after speaker and consultant to the oncology pharmaceutical industry.

Michael Vozniak, PharmD BCOP FHOPA, is the Associate Director of Pharmacy for Professional Practice and the PGY1 Residency Program Director at the Hospital of the University of Pennsylvania (HUP) in Philadelphia, PA. He received his doctor of pharmacy degree from the University of Pittsburgh. He completed his PGY1 Pharmacy Practice Residency at the University of Kentucky and his PGY2 Oncology Pharmacy Residency at the University of Pittsburgh Medical Center. Dr. Vozniak initially worked as an Oncology Clinical Pharmacy Specialist for almost 10 years at HUP. He helped to care for patients with a wide variety of malignancies from gynecologic to hematologic and allogeneic stem cell transplant patients. Dr. Vozniak served on the HOPA Board of Directors as President and Secretary and he has served on various committees including Health Policy, Nominations and Standards. His current role focuses on providing quality pharmacy services and meaningful pharmacist-patient engagement to enhance knowledge and understanding of medications.

HOPA

HOPA is a nonprofit professional organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates provide the best possible cancer care. HOPA supports research, conducts educational conferences to advance knowledge, encourages professional development and advocates for health policy issues that improve patient care. HOPA has more than 2,500 members and includes oncology pharmacists, as well as pharmacy administrators, researchers, residents, interns and technicians specializing in hematology/oncology practice.

###